Xilio Therapeutics, Inc. Common Stock

Xilio Therapeutics granted non-qualified stock options to purchase 3,257 shares to two new employees at an exercise price of $8.48 per share on April 1, 2026. The options have a ten-year term with a 25% vesting on the first anniversary and remaining 75% vesting monthly over three years, subject to continued employment.

Xilio Therapeutics announced the pricing of an underwritten offering of 74.78 million pre-funded warrants at $0.5349 per warrant, expected to raise approximately $40 million in gross proceeds. The financing was led by existing investor Coastlands Capital and included participation from Gilead Sciences, OrbiMed, and Perceptive Advisors. Proceeds w...

Xilio Therapeutics will present clinical and preclinical data on tumor-activated immuno-oncology therapies at the Society for Immunotherapy of Cancer's annual meeting in November 2025, highlighting research on vilastobart, efarindodekin alfa, and masked T cell engager programs.

Xilio Therapeutics announced the closing of a $50.0 million public offering, with the potential for up to $150.0 million in total gross proceeds if all warrants are exercised. The financing was co-led by new investors Coastlands Capital and Frazier Life Sciences, and included participation from Gilead Sciences, Logos Capital, and Samsara BioCapit...

Xilio Therapeutics, a clinical-stage biotechnology company, announced a proposed public offering of pre-funded warrants, Series A, B, and C warrants to purchase shares of common stock. The company plans to use the net proceeds to advance the development of its product candidates and for general corporate purposes.